Cargando…
Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a n...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533683/ https://www.ncbi.nlm.nih.gov/pubmed/23293509 http://dx.doi.org/10.2147/OPTH.S30951 |